Corticotrophin-releasing factor gene transcription is directly activated after deprivation of glucocorticoids in hypothalamic cells.
Corticotrophin-releasing factor (CRF) plays a central role in controlling the hypothalamic-pituitary-adrenal axis during stressful periods. CRF neurones are activated in the hypothalamic paraventricular nucleus (PVN) in response to stress, whereas the activated CRF neurones in the PVN are suppressed by glucocorticoids. Glucocorticoids may act directly on CRF neurones because glucocorticoid receptors are expressed highly on these neurones in the PVN. CRF expression levels in the PVN are also increased by adrenalectomy in vivo. The signalling pathways involved in the control of CRF gene transcription in the hypothalamus when negative feedback by glucocorticoids after adrenalectomy is lost remain undetermined. We investigated whether CRF gene transcription is regulated by both glucocorticoids and glucocorticoid withdrawal in hypothalamic cells. The present study demonstrates that CRF gene transcription activity and mRNA levels in the hypothalamic 4B cells were not modulated by incubation with dexamethasone for a short 2-h period, although they were stimulated by incubation for longer than 5 h. CRF gene transcription activity and mRNA levels were increased after 2 h of dexamethasone deprivation. The cAMP-response element (CRE) on the promoter was the main region that is regulated by both glucocorticoids and glucocorticoid withdrawal. We observed that the intracellular cAMP production levels were transiently increased 30 min after the removal of dexamethasone, whereas they were also increased 2.5 h after incubation with dexamethasone without the removal. Phosphorylated-CRE-binding protein (CREB)/CREB protein levels were also increased rapidly after the deprivation of glucocorticoids via an adenylate cyclase pathway. Therefore, the phosphorylation of CREB contributes to the activation of CRF gene transcription after the deprivation of glucocorticoids in hypothalamic cells.
Kageyama
K
K
Department of Endocrinology and Metabolism, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori, Japan. kkageyama@hkg.odn.ne.jp
Akimoto
K
K
Suda
T
T
D002478:Cells, Cultured; D003346:Corticotropin-Releasing Hormone / Q000235:genetics* / Q000378:metabolism; D000242:Cyclic AMP / Q000378:metabolism; D017362:Cyclic AMP Response Element-Binding Protein / Q000235:genetics / Q000378:metabolism; D003907:Dexamethasone / Q000494:pharmacology; D005786:Gene Expression Regulation / Q000187:drug effects; D005938:Glucocorticoids / Q000172:deficiency* / Q000494:pharmacology*; D006801:Humans; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism*; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D010766:Phosphorylation / Q000187:drug effects; D011401:Promoter Regions, Genetic / Q000187:drug effects; D011494:Protein Kinases / Q000378:metabolism; D013997:Time Factors; D014158:Transcription, Genetic / Q000187:drug effects; D014162:Transfection
D017362:Cyclic AMP Response Element-Binding Protein; D005938:Glucocorticoids; D003907:Dexamethasone; D003346:Corticotropin-Releasing Hormone; D000242:Cyclic AMP; D011494:Protein Kinases